Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: Results from the open-label period of a phase II randomized controlled trial (faSScinate)
Khanna D et al. Ann Rheum Dis 2018; 77:212–220. doi: 10.1136/annrheumdis-2017-211682
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.